• Busulfan (SKU A8386): Precision in Senescence & Germ Cell Re

  2026-05-11

  This article delivers scenario-driven guidance for deploying Busulfan (SKU A8386) as a robust DNA alkylating agent in cell viability and germ cell depletion assays. Drawing on validated protocols and recent genetic tracing studies, it addresses real lab challenges—optimizing reproducibility, interpreting cytotoxicity data, and selecting reliable suppliers. Readers gain actionable insight into Busulfan’s applications in senescence induction and germline modeling, grounded in quantitative evidence and best practices.

• Angiotensin I Decapeptide: Precision Tools for RAS Research

  2026-05-11

  APExBIO’s Angiotensin I (human, mouse, rat) empowers cardiovascular and neuroendocrine research with reproducible, high-fidelity performance. Discover advanced workflows, troubleshooting strategies, and cross-study insights for optimal renin-angiotensin system modeling.

• RITA (NSC 652287): Transforming Renal Carcinoma Workflows

  2026-05-10

  RITA (NSC 652287) delivers potent, selective p53 activation in renal carcinoma research, enabling precise apoptosis assays and robust tumor xenograft outcomes. This article details advanced protocol tweaks, troubleshooting strategies, and workflow innovations grounded in recent cancer biology methodology.

• Lipid Scrambling Modulates Ferroptosis and Tumor Immunity

  2026-05-09

  Yang et al. reveal that TMEM16F-mediated lipid scrambling on the plasma membrane acts as a late-phase suppressor of ferroptosis, protecting cells from membrane collapse and promoting tumor immune evasion. Their work identifies lipid scrambling as a promising therapeutic target, with implications for cancer immunotherapy and redox biology.

• Chloroquine in Translational Research: Mechanisms and Strate

  2026-05-08

  Explore the mechanistic depth and strategic edge of Chloroquine (N4-(7-chloroquinolin-4-yl)-N1,N1-diethylpentane-1,4-diamine) for translational researchers. This thought-leadership article integrates molecular insights, competitive context, protocol guidance, and a forward-looking vision, positioning APExBIO’s Chloroquine as a cornerstone for rigorous and innovative studies in autophagy, immune signaling, and disease modeling.

• Fulvestrant (ICI 182,780): Advanced Workflows for ER Antagon

  2026-05-08

  Fulvestrant (ICI 182,780) enables precise targeting of estrogen receptor signaling in breast cancer models, combining robust ERα degradation with proven synergy in chemotherapy sensitization. Discover optimized protocols, troubleshooting insights, and practical translation of recent immunomodulatory research to supercharge your endocrine therapy resistance studies.

• Hydrocortisone in Translational Research: Mechanisms to Mode

  2026-05-07

  This article explores hydrocortisone’s mechanistic role in translational research, focusing on its impact in inflammation model systems, stress response mechanisms, and neuroprotection, while offering strategic guidance for protocol optimization. Drawing on the latest mechanistic research and leveraging STAMBPL1/TRIM21 axis insights, we contextualize APExBIO’s hydrocortisone as a benchmark tool for translational scientists navigating the evolving landscape of immune modulation and disease modeling.

• AMD-070 Hydrochloride: Empowering Precision CXCR4 Antagonist

  2026-05-07

  Mavorixafor hydrochloride (AMD-070 hydrochloride) from APExBIO stands out as a potent and selective CXCR4 antagonist, enabling advanced workflows in anti-HIV research, rare disease modeling, and cell migration studies. This guide distills evidence-based protocols, advanced troubleshooting, and novel insights from landmark studies—bridging foundational mechanisms to robust, reproducible experimental success.

• Ruthenium Red: Advanced Ca2+ Transport Inhibitor in Mechanot

  2026-05-06

  Ruthenium Red delivers unparalleled specificity for probing cytoskeleton-dependent calcium signaling and autophagy. Its dual-site Ca2+-ATPase inhibition empowers researchers to dissect mechanotransduction and inflammation pathways with confidence.

• Patient-Derived Gastric Cancer Assembloids: Modeling Tumor-S

  2026-05-06

  This study introduces a novel gastric cancer assembloid model integrating patient-matched tumor organoids and diverse stromal subpopulations. By more accurately recapitulating the tumor microenvironment, the model enables detailed investigation of drug responses and resistance mechanisms, supporting advances in personalized therapeutic strategies.

• Vitamin C-Induced ROS-Iron-Calcium Crosstalk in Osteosarcoma

  2026-05-05

  This study reveals that high-dose, redox-active vitamin C triggers a unique form of non-apoptotic cell death in human osteosarcoma via intracellular ROS-iron–calcium signaling and mitochondrial dysfunction. The findings offer a mechanistic basis for targeted metabolic disruption in aggressive bone tumors and highlight new avenues for cell death pathway research.

• Vitamin C in Organoid Models: Protocols for Cancer & Antivir

  2026-05-05

  Vitamin C (ascorbic acid) is redefining organoid-based cancer and antiviral research with its potent, reproducible effects on tumor cell growth and viral pathogenesis. Leveraging high-purity Vitamin C from APExBIO, researchers can optimize experimental workflows for robust apoptosis induction, antiviral screening, and translational endpoint discovery.

• Quercetin Blocks Ferroptosis to Alleviate Liver Injury in Wi

  2026-05-04

  This study uncovers quercetin's direct inhibition of the ACSL4/LPCAT3/ALOX15 pathway, providing first-in-field evidence that the compound blocks ferroptosis and mitigates hepatic injury in Wilson’s disease models. The findings support quercetin’s utility as a mechanistically validated PI3K inhibitor and ferroptosis modulator, offering translational value for liver pathology and beyond.

• Vitamin C (CAS 50-81-7): Precision Anticancer Assays & Organ

  2026-05-04

  Explore how Vitamin C (ascorbic acid) enables high-precision cancer research through quantitative apoptosis assays and advanced organoid integration. This article provides a unique, evidence-driven guide for leveraging Vitamin C in translational oncology.

• Recombinant Annexin V: Expression, Purification, and Apoptos

  2026-05-03

  This article examines the methodological advances in the expression and purification of recombinant annexin V for detecting apoptotic cell membrane changes. The reference study introduces a streamlined bacterial production protocol and highlights annexin V's specificity for phosphatidylserine exposure, a hallmark of early apoptosis. These findings underpin improvements in flow cytometry and fluorescence-based apoptosis assays, with practical implications for cellular and gastrointestinal disorder research.

11771 records 1/785 page Next 12345 下5页 Last page